

United in solidarity against filovirus threats

Building research readiness for a future filovirus outbreak

Ana Maria Henao-Restrepo MD MSc
Lead WHO R&D Blueprint for Epidemics
WHO Health Emergencies programme



An approach to support assessment of candidate MCMs and enhance outbreak prevention and control

1 Prioritization

WHO Independent expert process to prioritize candidate vaccines



A WHO process for prioritization of candidate vaccines by an independent WHO Technical Advisory Groups on candidate vaccine and treatments prioritization

2 Availability

Agreement on availability and access to candidate vaccines and therapeutics



Decisions are informed by outcomes of the prioritization process on minimum number of candidate product doses required for research during outbreaks and that need to be available.

3 Clinical trials

CORE protocols and platforms to promptly initiate trials with equitable access to research



Ministries and researchers in affected countries are in the driving seat and integrated into the response.

CORE protocols for viral and bacterial families designed and approved in advance

4 Agreements

Prior agreement on legal collaboration, insurance, indemnity and liability



A partnership model and signed agreements with Ministries of Health and developers with **access** to MCMs considered, and a framework for insurance and liability arrangements.

5 Funding

Access to readily available funding through committed financing mechanism



Signed agreements with contributors; aimed at a simple approval process for releasing of funds and simplifying financial reporting.

6 Collaborative approach

To foster an open flexible collaborative mechanism that allows a variety of contributors




Including pathogen and trial experts, **local researchers, and outbreak response teams** to help adjust and implement research as needed



R&D Blueprint
Powering research
to prevent epidemics

17 countries at risk have joined the research preparedness efforts



Angola, Congo, DRC, Ghana, Guinea, Equatorial Guinea, Ivory Coast, Kenya, Liberia, Mali, Nigeria, Rwanda, Sierra Leone, South Africa, South Sudan, Tanzania, Uganda

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO 2014. All rights reserved

MARVAC CONSORTIUM

MARVAC is a WHO-coordinated consortium to promote international collaboration for the development of MVD vaccines (and now other MCMs).

This consortium includes shareholders from industry, nonprofit organizations, government, and academia to maximize its effectiveness (and importantly, researchers from countries at risk).

This joint venture is supported by the following principles:

- (1) sharing of assays and reagents;
- (2) promoting access to laboratory networks in endemic countries; and
- (3) promoting support for development (and evaluation) of upcoming vaccine and therapeutic candidates.